Levodopa–carbidopa intestinal gel in advanced Parkinson’s disease: long-term results from COSMOS

[11] Bergmann L(1988)Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility Neurology 38 S65-406

[12] Yegin A(2018)Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson's disease J Parkinsons Dis 8 399-807

[13] Onuk K(2011)The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease Mov Disord 26 802-480

[14] Barch D(2019)Parkinson's disease and Parkinsonism Am J Med 132 474-95

[15] Odin P(2021)Different catechol-o-methyl transferase inhibitors in Parkinson's disease: a bayesian network meta-analysis Front Neurol 12 89-189

[16] Brooks DJ(2010)Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data Mov Disord 25 163-1387

[17] Wang L(2016)Medication regimen complexity and polypharmacy as factors associated with all-cause mortality in older people: a population-based cohort study Ann Pharmacother 50 4315489-1061

[18] Li J(2010)Toxicology and safety of COMT inhibitors Int Rev Neurobiol 95 103-1752

[19] Chen J(2020)Self-reported nonadherence predicts changes of medication after discharge from hospital in people with Parkinson's disease Parkinsons Dis 2020 1382-837

[20] Contin M(2020)What predicts different kinds of nonadherent behavior in elderly people with Parkinson's disease? Front Med (Lausanne) 7 1053-939

[11] Bergmann L(1988)Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility Neurology 38 S65-406

[12] Yegin A(2018)Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson's disease J Parkinsons Dis 8 399-807

[13] Onuk K(2011)The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease Mov Disord 26 802-480

[14] Barch D(2019)Parkinson's disease and Parkinsonism Am J Med 132 474-95

[15] Odin P(2021)Different catechol-o-methyl transferase inhibitors in Parkinson's disease: a bayesian network meta-analysis Front Neurol 12 89-189

[16] Brooks DJ(2010)Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data Mov Disord 25 163-1387

[17] Wang L(2016)Medication regimen complexity and polypharmacy as factors associated with all-cause mortality in older people: a population-based cohort study Ann Pharmacother 50 4315489-1061

[18] Li J(2010)Toxicology and safety of COMT inhibitors Int Rev Neurobiol 95 103-1752

[19] Chen J(2020)Self-reported nonadherence predicts changes of medication after discharge from hospital in people with Parkinson's disease Parkinsons Dis 2020 1382-837

[20] Contin M(2020)What predicts different kinds of nonadherent behavior in elderly people with Parkinson's disease? Front Med (Lausanne) 7 1053-939